Clinical Trial Update: Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21 [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating a prostate cancer vaccine using MUC-2-KLH conjugate with the QS21 adjuvant has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• MUC-2-KLH conjugate vaccine (MUC-2-KLH conjugate)
• QS-21 adjuvant (QS-21 adjuvant)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Prostate Cancer | Phase 1 | Status: COMPLETED